1 TITLE PAGE:

2

4

3 The Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19 Infection

Sejal Morjaria MD^{*1,12}, Allen W Zhang PhD^{*2}, Anna Kaltsas MD MS^{1,12}, Rekha Parameswaran³, Dhruvkumar
 Patel MS⁴, Wei Zhou MPH,MSc^{5,6}, Jacqueline Predmore¹, Rocio Perez-Johnston MD^{3,7}, Justin Jee MD, PhD⁸,
 Miguel-Angel Perales^{9,13}, Anthony F. Daniyan MD^{11,12,13}, Ying Taur MD MPH^{1,12}, Sham Mailankody MD^{11,12,13}

9

10 Author Affiliations:

- 11 ¹Infectious Disease, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
- 12 ²MD/PhD Program, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
- ¹³ ³Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
- 14 ⁴Department of Quality and Safety, Memorial Sloan Kettering Cancer Center, NY, NY
- 15 ⁵Operation Excellence, Memorial Sloan Kettering Cancer Center, NY, NY
- 16 ⁶Advanced Practice Provider Department, Memorial Sloan Kettering Cancer Center, NY, NY
- 17 ⁷Department of Radiology, Memorial Sloan Kettering Cancer Center, NY, NY
- 18 ⁸Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY, USA
- ⁹Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering, NY, NY
- 20 ¹⁰Leukemia Service, Memorial Sloan Kettering Cancer Center, NY, NY
- 21 ¹¹Myeloma Service, Memorial Sloan Kettering Cancer Center, NY, NY
- 22 ¹²Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, NY, NY
- 23 ¹³Weill Cornell Medical College, NY, NY
- ²⁴ *SM and AZ are co-first authors; AD, YT, and SM are co-senior authors
- 25 **Corresponding Author Contact Information:**
- 26 Sham Mailankody, MBBS
- 27 Memorial Sloan Kettering Cancer Center
- 28 1275 York Ave, New York, NY 10065
- 29 Phone: 212-639-2131; Fax: 929-321-8155; Email: mailanks@mskcc.org
- 30
- 31

32 Background:

33 Neutropenia is commonly encountered in cancer patients, and recombinant human granulocyte colony-34 stimulating factor (G-CSF, filgrastim) is widely given to oncology patients to counteract neutropenia and 35 prevent infection. G-CSF is both a growth factor and cytokine that initiates proliferation and 36 differentiation of mature granulocytes. However, the clinical impact of neutropenia and G-CSF use in 37 cancer patients, who are also afflicted with coronavirus disease 2019 (COVID-19), remains unknown. 38 Methods: 39 An observational cohort of 304 hospitalized patients with COVID-19 at Memorial Sloan Kettering Cancer 40 Center was assembled to investigate links between concurrent neutropenia (N=55) and G-CSF 41 administration (N=16) on COVID-19-associated respiratory failure and death. These factors were assessed 42 as time-dependent predictors using an extended Cox model, controlling for age and underlying cancer 43 diagnosis. To determine whether the degree of granulocyte response to G-CSF affected outcomes, a 44 similar model was constructed with patients that received G-CSF, categorized into "high"- and "low"-45 response, based on the level of absolute neutrophil count (ANC) rise 24 hours after growth factor 46 administration.

47 **Results**:

Neutropenia (ANC < 1 K/mcL) during COVID-19 course was not independently associated with severe respiratory failure or death (HR: 0.71, 95% CI: 0.34-1.50, *P* value: 0.367) in hospitalized COVID-19 patients. When controlling for neutropenia, G-CSF administration was associated with increased need for high oxygen supplementation and death (HR: 2.97, 95% CI: 1.06-8.28, *P* value: 0.038). This effect was predominantly seen in patients that exhibited a "high" response to G-CSF based on their ANC increase post-G-CSF administration (HR: 5.18, 95% CI: 1.61-16.64, *P* value: 0.006).

54 **Conclusion**:

55 Possible risks versus benefits of G-CSF administration should be weighed in neutropenic cancer patients

56 with COVID-19 infection, as G-CSF may lead to worsening clinical and respiratory status in this setting.

57 Introduction:

58 Neutropenia is a common side-effect of anti-cancer therapies, and recombinant human granulocyte 59 colony stimulating factor (G-CSF, filgrastim) is often given to cancer patients for ongoing or impending 60 neutropenia. During the ongoing SARS-CoV-2 pandemic, there is uncertainty about the effect of 61 commonly used medications like G-CSF on clinical outcomes. The mechanism of action of G-CSF 62 (stimulates both cytokine and neutrophil production),¹ the association of G-CSF with acute lung injury 63 (ALI) or adult respiratory distress syndrome (ARDS),^{2,3} and what is now known about the pathogenesis of 64 COVID-19- resulting in cytokine storm in some patients, has raised concerns about the safety profile of G-65 CSF in COVID-19 patients. Moreover, lung findings from autopsies of COVID-19 patients have shown 66 neutrophil extravasation in the alveolar space,^{4,5,6} raising concerns that G-CSF administration and the 67 resultant neutrophil expansion, could to lead to exaggerated neutrophil responses, thereby worsening 68 clinical outcomes in COVID-19 patients.

Our group published a case series describing the rapid clinical deterioration of three COVID-19 patients soon after receiving G-CSF. Herein, we sought to quantitatively estimate the clinical effects of G-CSF on a larger cohort of COVID-19 patients.⁷ Specifically, we asked: what are the effects of neutropenia and G-CSF administration on the clinical outcomes, respiratory failure or death, in patients with cancer and COVID-19 infection.

74 Methods

75 Study population

We included all 304 inpatients admitted within a window of [-5 days, +14 days] around a patient's COVID19-postive test date (day 0), between the dates of March 13, 2020 and May 15, 2020. Clinical outcomes
were monitored until May 19, 2020. If a patient reached a clinical endpoint (defined below) prior to

79 receiving G-CSF, they were excluded from the cohort. Patients with a diagnosis of acute myeloid leukemia 80 or myelodysplastic syndrome were not included in the analysis, as these patients are generally not 81 candidates for G-CSF administration. As we were primarily interested in whether or not G-CSF should be 82 administered for neutropenia in the context of a COVID-19 infection, patients that received G-CSF before 83 the first recorded occurrence of neutropenia (defined as ANC < 1 K/mcL) or prior to hospitalization were 84 excluded from the analysis. Furthermore, when stratifying patients that received G-CSF into high and low 85 responders, patients without ANC values on day 0 and day 1 of G-CSF administration were also excluded 86 from the analysis, as a log-fold change in ANC could not be computed for these patients. We define G-CSF 87 administration as the inpatient use of filgastrim or pegfilgastrim at any dose. The Memorial Sloan 88 Kettering Cancer Center (MSKCC) institutional review board approved the study.

89 Laboratory methods

90 COVID-19 status was determined using a nasopharyngeal swab to determine the presence of virus specific

91 RNA (MSKCC FDA EUA-approved assay and Cepheid®). COVID-19 RNA was detected using the Centers for

92 Disease Control and Prevention protocol targeting two regions of the nucleocapsid gene (N1 and N2) with

93 modifications described elsewhere. ^{8–10}

94 Data sources

Patient data was extracted from the MSKCC electronic health record. Patient medications, demographics, and outcomes (i.e. use of high-flow supplemental oxygen, mechanical ventilation or tracheostomy, and death), were extracted from a standardized-input institutional database. Respiratory failure was defined as oxygen supplementation of \geq 4 liters per minute on nasal cannula, high-flow nasal cannula, or any amount of oxygen on non-rebreather, Bi-Level Positive Airway Pressure (BIPAP), or mechanical ventilation.

101 Statistical analysis

| 102 | In the primary analysis, we applied an extended Cox model (Cox regression model) using age (binned |
|-----|---|
| 103 | into < 25, 25-50, 50-70, 70-80, 80-90, and >90 categories) and cancer type as time-independent |
| 104 | covariates. The first occurrence of neutropenia and the first administration of G-CSF (filgrastim or |
| 105 | pegfilgrastim) following COVID-19 positivity were introduced as binary time-dependent covariates in the |
| 106 | model. To minimize reverse causality, and since the earliest evidence of ANC recovery we had was a day |
| 107 | after G-CSF administration with few changes in the successive days, G-CSF events were encoded 1 day |
| 108 | following actual administration, to capture the timing of its expected effect. In a second analysis, G-CSF |
| 109 | response was additionally categorized into "high-response" and "low-response" groups and introduced |
| 110 | as mutually exclusive binary time-dependent covariates. High response was defined as a > |
| 111 | 50th percentile increase in ANC at day 1 post-G-CSF administration (compared to ANC values prior to G- |
| 112 | CSF administration) across all cases of G-CSF administration. For our cohort, this corresponded to an |
| 113 | increase in ANC of at least fourfold from day 0 to day 1 after G-CSF administration. |
| 114 | For survival analysis, starting time was defined as the time of COVID-19 diagnosis for each patient. To |
| 115 | verify that the significant hazard ratio associated with G-CSF administration was not solely due to |
| 116 | collinearity between the neutropenia and G-CSF variables, we also considered an alternative formulation |
| 117 | of the model, where starting time was instead defined as the time of first occurrence of neutropenia. The |
| 118 | number of days prior to neutropenia was added as a continuous time-independent variable to the model. |
| 119 | The primary analysis was conducted using a composite endpoint defined as the first occurrence of |
| 120 | respiratory failure (defined above) or death following COVID-19 diagnosis. For the alternate analysis, we |
| 121 | excluded death as an endpoint and only looked at patients that developed respiratory failure, as patients |
| 122 | that died without oxygen supplementation (n = 3) may have died of non-COVID-19-related causes. |
| 123 | All patient events were right-censored at the date of last follow-up or May 19, 2020. All analysis was |
| 124 | performed in R version 3.6.2 with the survival (version 3.1-11) and survminer (version 0.4.7) packages. ¹¹ |
| 125 | |

126 **Results**

127 We assembled a cohort of 304 hospitalized patients with cancer who tested positive for COVID-19 at 128 MSKCC between the dates of March 13, 2020 and May 15, 2020. These cases comprised a variety of cancer 129 types, including gastrointestinal malignancies (n=45, 14.8%), lung cancers (n=41, 13.5%), non-Hodgkin 130 lymphomas (n=39, 12.8%), and breast cancers (n=37, 12.2%), among others. In total, 55 (18.1%) patients 131 were neutropenic at some point during hospitalization, as defined by an ANC less than 1 K/mcL. Of these, 132 16 (48.4%) of patients received either filgrastim or pegfilgrastim (G-CSF) for neutropenia. A total of 103 133 (33.9%%) patients reached the primary endpoint: the development of respiratory failure. The patient 134 characteristics of all patients (n=304) are shown in Table 1. 135 The key clinical timepoints for patients (neutropenia, G-CSF administration, respiratory failure, or death) 136 for each patient (*prior to applying exclusion criteria) above are shown in Figure 1. The patient 137 characteristics of neutropenic inpatients that did (n=29) and did not receive G-CSF (n=55) are shown in 138 Table S1. Patient characteristics of both inpatients and outpatients with COVID-19 infection that did and 139 did not receive G-CSF with their clinical outcomes are shown in Tables S2-S3. A total of nine of 29 140 inpatients (31%) receiving G-CSF before application of exclusion criteria required >4L oxygen, compared 141 with 94 of 275 (34%) patients not receiving G-CSF.

142 A total of 16 patients were counted as having received G-CSF, based on our definition. To evaluate the 143 effect of neutropenia and G-CSF use on our primary composite endpoint defined as respiratory failure and 144 death from COVID-19, we applied an extended Cox model controlling for age and neutropenia while 145 stratifying by underlying cancer diagnosis (see Methods). As expected, age at enrollment greater than 90 146 (HR: 7.29, 95% CI: 2.72-19.52, P value: <0.001) was associated with significantly worse outcomes. In 147 contrast, being less than 50 years of age was associated with better outcomes. G-CSF use (HR: 2.97, 95% 148 CI: 1.06-8.28, P value: 0.038; Figure 2), but not neutropenia alone (HR: 0.71, 95% CI: 0.34-1.49, p value: 149 0.364), portended significantly worse outcomes in a multivariate model. These results were consistent

with those obtained using respiratory failure alone as the endpoint (HR: 3.01, 95% CI: 1.08-8.39, *P* value:
0.035; Figure S1), or when considering only neutropenic patients and using time of neutropenia as t=0
(HR for G-CSF: 4.62, 95% CI: 1.08-19.7, *P* value: 0.039; Figure S2).

153 To determine whether the neutrophil-inducing properties of G-CSF may relate to the poor outcomes 154 associated with G-CSF, we further considered the neutrophil concentrations in peripheral blood prior to 155 and immediately after G-CSF administration. As expected, ANC and ANC/ALC (ratio of absolute neutrophil 156 count to absolute lymphocyte count) values increased after G-CSF administration, and this increase was 157 predominantly limited to the day immediately following G-CSF administration (Figure 3A, 3C). In contrast, 158 ALC values remained more constant during this 1-day period (Figure 3B), and thus the rise in ANC/ALC is 159 largely attributable to ANC. We stratified patients that received G-CSF (n=16) based on their response to 160 ANC, computed as the log fold-change between ANC values 1 day after versus the day of G-CSF (day 0) 161 administration (Figure 4A). High-response patients (n=9; Figure 4B) were defined as those that 162 experienced a >4X rise in ANC, comprising the upper 50th percentile of the patients that received G-CSF. 163 Using these response categories, we modified the extended Cox model shown in Figure 2 to categorize G-164 CSF events as high- and low- response. As before, age greater than 90 (HR: 7.37, 95% CI: 2.75-19.76, P 165 value<0.001) was significantly associated with worse outcomes.

There were pronounced differences in risk associated with low- and high-response to G-CSF. While low response to G-CSF was not significantly associated with poorer outcomes (HR: 1.62, 95% CI: 0.40 - 6.54, *P* value: 0.5), high response to G-CSF was significantly associated with poorer outcomes (HR: 5.18, 95% CI: 1.61-16.64, *P* value: 0.006; **Figure 4B**). These results imply that the effect of G-CSF on outcomes is primarily driven by patients with robust increases in ANC following G-CSF administration. Interestingly, neutropenia was not statistically associated with worse outcomes.

7

Ten of the 16 patients that were neutropenic and received G-CSF had a pre-and-post chest radiograph and 6/10 (60%) demonstrated radiologic worsening within 7 days of receiving G-CSF **(Table S4)**; 3 patients that developed radiographic deterioration post-G-CSF use are shown in **Figure S3**.

175 Discussion

176 The COVID-19 pandemic has made delivering effective cancer care -- already a challenging endeavor --177 more difficult, given the balancing of competing risks of death from untreated cancer versus death or 178 serious complications from COVID-19 infection.^{12, 13, 14, 8, 15, 16} In this study, we evaluate the potential 179 impact of neutropenia and G-CSF use in cancer patients with concurrent COVID-19 infection. We observed 180 a higher likelihood of respiratory failure and death in patients that received G-CSF, particularly in the 181 subset of patients that exhibited a "high" response to G-CSF. Our observations also suggest that 182 neutropenia during COVID-19 illness itself was not an independent risk factor for adverse outcomes in 183 COVID-19 illness.

184 From published reports, it is becoming increasingly clear that rapid clinical deterioration can occur in some 185 patients because of the hyperactive immune response driving COVID-19 progression, causing an 186 overwhelming infiltration of inflammatory myeloid cells into the lungs (particularly monocytes, 187 macrophages and neutrophils),^{4,17-19} the so-called "cytokine storm". Zuo et al. used cell-free DNA as a 188 marker to detect neutrophil extracellular trap (NET) remnants in the blood and noted that these appeared 189 strongly correlated with absolute neutrophil counts, and elevated blood neutrophils forecast worst 190 outcomes. ⁶ Lung injury is one consequence of the cytokine storm that can progress into ALI or its more 191 severe form, ARDS.²⁰ Considering that neutrophil influx in the lung is a hallmark feature of ARDS,²¹ and 192 that ALI has already been reported as a potential complication of G-CSF use, ^{2,3} administering G-CSF to 193 certain cancer patients with COVID-19 for neutropenia may give clinicians pause. Similar concerns exist 194 for patients who receive chimeric antigen receptor T (CAR-T) cell therapy,²² where G-CSF administration

is generally avoided to prevent the overactivation of the immune system, given the already increased riskfor cytokine storm.

197 To best estimate the effects of neutropenia and G-CSF on our defined clinical outcomes, we encoded G-198 CSF as a time-dependent covariate, while controlling for neutropenia as another time-dependent 199 covariate. We also compared the clinical outcomes of patients that had different levels of response to G-200 CSF, finding that robust G-CSF neutrophil response was associated with substantially higher hazard (HR: 201 5.18, 95% CI: 1.61-16.64, P value: 0.006) for respiratory decompensation, compared to those that had less 202 robust levels of response to G-CSF (HR: 1.62, 95% CI: 0.40-6.54, P value: 0.500). We also show that soon 203 after G-CSF administration, there is a substantial increase in the neutrophil to lymphocyte ratio (ANC/ALC), 204 previously shown to be an independent risk factor for mortality in hospitalized patients with COVID-19.²³ 205 To our knowledge, this is the first study describing the course of COVID-19 infection in selected cancer 206 patients who received G-CSF for neutropenia.

207 This study is not without its limitations. The study ultimately included a modest number of patients 208 receiving G-CSF (N=16). In this observational cohort, unaccounted confounding factors are plausible. This 209 analysis attempted to assess G-CSF over a wide range of cancers; tumor-specific effects were difficult to 210 ascertain. We also limit our primary analysis to the subset of patients who were hospitalized, to be able 211 to assess our clinical endpoints of interest (respiratory failure or death). As a result, the potential for G-212 CSF to worsen outcomes, suggested here, may not be generalizable to outpatients. While our analysis 213 adjusts for the neutrophil count prior to G-CSF administration, we have not incorporated data on 214 concurrent therapies such as chemotherapies or surgery prior to the diagnosis of COVID-19 in these 215 patients.

216 Interestingly, in lieu of the COVID-19 pandemic, the National Comprehensive Cancer Network and the 217 American Society of Clinical Oncology have released updated guidelines on this very issue, lowering the 218 threshold for the use of G-CSF to now include those chemotherapy regimens that carry a 10 to 20 percent

9

219 risk of fever in the setting of neutropenia²⁴. Although there is a potential role for G-CSF and its prophylactic 220 use following the administration of chemotherapy when neutropenia is anticipated (primary prophylaxis) 221 and during retreatment after a previous cycle of chemotherapy had caused fever during neutropenia 222 (secondary prophylaxis),²⁵ G-CSF has not definitively been shown to actually reduce infection-related 223 mortality. ^{26,27,28} Its benefits therefore must be carefully weighed against the potential risk of harm in the 224 patient with cancer and active COVID-19 infection, particularly one requiring hospitalization. Until 225 additional data from larger studies are available, in areas with high or increasing incidence of COVID-19, 226 perhaps the use of G-CSF in patients with confirmed COVID-19 could be reserved for those patients who 227 are classified as having a higher risk of complications- those that have profound neutropenia due to 228 chemotherapy.²⁹ 229 Acknowledgements: 230 The authors would like to thank Susan Weill who works in the Design and Creative Services, Marketing 231 and Communication Department at MSKCC who helped to create the figures for this manuscript. 232 **Funding Sources:** 233 This research was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748. The content 234 is solely the responsibility of the authors and does not necessarily represent the official views of the 235 National Institutes of Health. This study was supported by the Memorial Sloan Kettering Cancer Center 236 K12 Paul Calabresi Career Development Award for Clinical Oncology (to A.F.D.) This work was further 237 supported by the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. 238 the Sawiris Foundation; the Society of Memorial Sloan Kettering Cancer Center; MSK Cancer Systems 239 Immunology Pilot Grant, and Empire Clinical Research Investigator Program, the Memorial Sloan Kettering 240 Cancer Center Department of Medicine and Weill Cornell Medicine. 241 **Competing Interests:**

| 242 | JJ has a patent licensed by MDSeq, Inc. MAP has received honoraria from Abbvie, Bellicum, Bristol-Myers |
|-----|--|
| 243 | Squibb, Incyte, Kite (Gliead), Merck, Novartis, Nektar Therapeutics, and Takeda; serves on DSMBs for |
| 244 | Cidara Therapeutics, Servier and Medigene, and the scientific advisory boards of MolMed and |
| 245 | NexImmune; and has received research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi |
| 246 | Biotec. |
| 247 | |
| 248 | |
| 249 | |
| 250 | |
| 251 | |
| 252 | |
| 253 | |
| 254 | |
| 255 | |
| 256 | |
| 257 | |
| 258 | |
| 259 | |
| 260 | |
| 261 | |
| 262 | |
| 263 | |
| 264 | |
| 265 | |

266 Figure Captions:

- **Table 1.** Demographics and baseline characteristics of all inpatients with COVID-19 (n = 304)
- 268 **Table S1:** Demographics and baseline characteristics of neutropenic patients that did (n= 29) and did not
- 269 receive G-CSF (n= 55).
- 270 **Table S2:** Demographics and baseline characteristics of all outpatients with COVID-19 (n = 530)

271 **Table S3:** Descriptive statistics (frequencies as %) of both inpatients and outpatients that did and did not

- 272 receive G-CSF and non-G-CSF with clinical endpoint. This does not account for time dependence of G-CSF
- risk as primary analysis does
- 274 **Table S4:** Radiologic evolution of patients receiving G-CSF. Baseline X-Ray of patients was determined as

275 normal or abnormal if airspace or reticulonodular opacities were noted. X-Ray post G-CSF was compared

to baseline assessing radiologic evolution and categorizing it as: unchanged, increased or decreased.

Figure 1: Timelines of all hospitalized, neutropenic (ANC < 1 K/mcL) patients who received Granulocytecolony-stimulating factor (G-CSF (top panel)) versus those patients that were neutropenic but did not receive G-CSF (bottom panel) showcasing their relevant clinical endpoints (neutropenia, G-CSF administration, "respiratory failure" (defined in Methods). Three patients that received G-CSF as an outpatient, subsequently admitted to the hospital were counted in subsequent analysis as being neutropenic but not receiving G-CSF.

Figure 2: Forest plot showing the effect (HR = Hazard Ratio) of Granulocyte colony-stimulating factor (G-CSF) on the composite endpoint of the first occurrence of "respiratory failure" (defined in Methods) or death. Hazard ratios were computed with an extended Cox model, using binned ages and cancer type as time-independent covariates and neutropenia and G-CSF as time-dependent covariates.

Figure 3. Lab values of: Absolute Neutrophil Count (ANC (K/mcL)) (a), Absolute Lymphocyte Count (ALC (K/mcL)) (b), and their ratio, ANC/ALC (c) within a 4 day window of G-CSF administration. Day 0

corresponds to the date of G-CSF administration. The black dashed line in each panel corresponds to the
 average lab value per day for all patients.

291 Figure 4: (a) Log-fold change values of absolute neutrophil count (ANC) obtained 1 day after G-CSF 292 administration and prior to G-CSF administration for the n=25 patients that received G-CSF. Patients were 293 stratified into "high" (to the right of the dashed orange line; fourfold increase in ANC day 1 post-G-CSF) 294 or "low" (to the left of the dashed red line) responders based on these values (threshold of ANC = 2, 295 corresponding to the 50th percentile). (b) Forest plot showing the effect (HR = Hazard Ratio) of high- and 296 low-response to G-CSF on the first occurrence of "respiratory failure" (defined in Methods). Hazard ratios 297 were computed with an extended Cox model, using binned ages and cancer type as time-independent 298 covariates, and neutropenia and G-CSF (high- and low-response) as time-dependent covariates. 299 Figure S1: Forest plot showing the effect (HR = Hazard Ratio) of Granulocyte colony-stimulating factor (G-

300 CSF) on the first occurrence of "respiratory failure" (defined in Methods). Hazard ratios were computed 301 with an extended Cox model, using binned ages and cancer type as time-independent covariates and 302 neutropenia and G-CSF as time-dependent covariates.

Figure S2: Forest plot showing the effect (HR = Hazard Ratio) of G-CSF administration on the first occurrence of "respiratory failure" (defined in Methods), using the time of the first occurrence of neutropenia as t=0. Hazard ratios were computed with an extended Cox model, using binned ages, cancer type, and the time to neutropenia (from COVID-19+ date) as time-independent covariates and G-CSF as a time-dependent covariate.

Figure S3: A i: Portable chest X-Ray performed the day of G-CSF administration demonstrating right basilar
 and left mid lung patch opacities. A ii: A day after the administration the airspace opacities increased
 bilaterally

B i: Portable chest X-Ray performed two days prior to administration of G-CSF demonstrating bilateral
 predominantly bibasilar patchy opacities B ii and B iii: Axial and coronal images two days post G-CSF

13

- 313 administration, demonstrating peripheral and peribronchovascular airspace opacities predominantly in
- 314 the lower lobes
- **C** i: Portable chest X-ray at day 0 of G-CSF administration demonstrating faint right basilar opacity. C ii:
- 316 day 4 post G-CSF administration, bilateral patchy opacities noted involving both upper and lower zones C
- 317 iii: Day 13 post administration, increased bilateral diffuse reticular and airspace opacities

337 References:

- 338 1. Martins, A., Han, J. & Kim, S. O. The multifaceted effects of granulocyte colony-stimulating factor in
- immunomodulation and potential roles in intestinal immune homeostasis. *IUBMB Life* **62**, 611–617
- 340 (2010).
- 341 2. Karlin, L. et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone
- 342 *Marrow Transplant.* **36**, 245–250 (2005).
- 343 3. Wiedermann, F. J. Acute lung injury during G-CSF-induced neutropenia recovery: effect of G-CSF on
- 344 pro- and anti-inflammatory cytokines. *Bone Marrow Transplant.* **36**, 731–731 (2005).
- 345 4. Barnes, B. J. *et al.* Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *J. Exp. Med.*
- **217**, (2020).
- 5. Fox, S. E. *et al.* Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New
 Orleans. *Pathology* (2020).
- 349 6. Zuo, Y. *et al.* Neutrophil extracellular traps in COVID-19. *JCI Insight* 5, (2020).
- 350 7. Nawar, T. *et al.* Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just
- 351 the bone marrow? *Am. J. Hematol.* (2020) doi:10.1002/ajh.25870.
- 8. Robilotti, E. V. *et al.* Determinants of COVID-19 disease severity in patients with cancer. *Nat. Med.* 1–
 6 (2020).
- 354 9. Website. https://www.fda.gov/media/134922/download.
- 355 10. Website. https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer- probes.pdf.
- 356 11. Website. http://www.R-project.org/.
- 12. Calabrò, L. *et al.* Challenges in lung cancer therapy during the COVID-19 pandemic. *Lancet Respir Med*8, 542–544 (2020).
- 359 13. Yu, J., Ouyang, W., Chua, M. L. K. & Xie, C. SARS-CoV-2 Transmission in Patients With Cancer at a
- 360 Tertiary Care Hospital in Wuhan, China. *JAMA Oncology* (2020) doi:10.1001/jamaoncol.2020.0980.

15

| 361 | 14. | Dai, M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study |
|-----|-----|---|
| 362 | | during the COVID-19 outbreak. <i>Cancer Discovery</i> CD-20 (2020) doi:10.1158/2159-8290.cd-20-0422. |
| 363 | 15. | Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. |
| 364 | | Lancet 395 , 1907–1918 (2020). |
| 365 | 16. | Yang, K. et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer |
| 366 | | and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. The Lancet Oncology vol. |
| 367 | | 21 904–913 (2020). |
| 368 | 17. | Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, |
| 369 | | 1033–1034 (2020). |
| 370 | 18. | Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. |
| 371 | | Med. 26 , 842–844 (2020). |
| 372 | 19. | Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science vol. 368 473–474 |
| 373 | | (2020). |
| 374 | 20. | Shimizu, M. Clinical Features of Cytokine Storm Syndrome. in Cytokine Storm Syndrome (eds. Cron, |
| 375 | | R. Q. & Behrens, E. M.) vol. 69 31–41 (Springer International Publishing, 2019). |
| 376 | 21. | Potey, P. M., Rossi, A. G., Lucas, C. D. & Dorward, D. A. Neutrophils in the initiation and resolution of |
| 377 | | acute pulmonary inflammation: understanding biological function and therapeutic potential. J. |
| 378 | | Pathol. 247 , 672–685 (2019). |
| 379 | 22. | Toxicity and management in CAR T-cell therapy. <i>Molecular Therapy - Oncolytics</i> 3 , 16011 (2016). |
| 380 | 23. | Liu, Y. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized |
| 381 | | patients with COVID-19. J. Infect. 81, e6–e12 (2020). |
| 382 | 24. | NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/. |
| 383 | 25. | Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic |
| | | |

384 patients with cancer: 2010 update by the infectious diseases society of america. *Clin. Infect. Dis.* **52**,

- 385 e56–93 (2011).
- Sung, L., Nathan, P. C., Lange, B., Beyene, J. & Buchanan, G. R. Prophylactic Granulocyte Colony Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile
 Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized
 Controlled Trials. *Journal of Clinical Oncology* vol. 22 3350–3356 (2004).
- 390 27. Bohlius, J., Reiser, M., Schwarzer, G. & Engert, A. Impact of granulocyte colony-stimulating factor
- 391 (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review.
- 392 British Journal of Haematology vol. 122 413–423 (2003).
- 393 28. Bohlius, J., Reiser, M., Schwarzer, G. & Engert, A. Granulopoiesis-stimulating factors to prevent
- adverse effects in the treatment of malignant lymphoma. *Cochrane Database Syst. Rev.* CD003189
 (2004).
- 396 29. Freifeld, A. G. *et al.* Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial
- 397 Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of
- 398 America. Clinical Infectious Diseases vol. 52 427–431 (2011).

399

Figure 1





Patient

Figure 2

| | | · · · · · · · · · · · · · · · · · · · | |
|-------------------------|------------------------|---------------------------------------|--|
| | - | | P value |
| 51-70 <i>(N=147)</i> | reference | | |
| ≤25 (N=12) | 0.27 (0.05 – 1.29) | ⊢−−−−− | 0.101 |
| 26-50 (N=40) | 0.51 (0.28 – 0.94) | ⊢ | 0.030* |
| 71-80 (N=70) | 1.17 (0.79 – 1.73) | H <mark>a</mark> H | 0.439 |
| 81-90 (N=27) | 0.65 (0.34 – 1.25) | ⊢∎ 1 | 0.199 |
| >90 (N=5) | 7.29 (2.72 – 19.52) | ⊢ | |
| (N=40) | 0.71 (0.34 – 1.49) | ⊢∎ _∔_1 | 0.364 |
| (N=16) | 2.97 (1.06 – 8.28) |) - (| 0.038* |
| Breast (N=37) | reference | | |
| CNS (N=6) | 2.55 (0.67 – 9.63) | ⊢ −−−−− − | 0.168 |
| GI (N=44) | 1.27 (0.65 – 2.46) | ⊢∎ (| 0.485 |
| GU (N=33) | 1.04 (0.48 – 2.27) | ⊢ | 0.912 |
| Gyn (N=15) | 1.43 (0.58 – 3.53) | ⊢ | 0.442 |
| HL (N=5) | 0.28 (0.03 – 2.35) | | 0.243 |
| HNT (N=7) | 2.92 (1.04 – 8.16) | | 0.041* |
| Leukemia (N=21) | 2.08 (1.00 - 4.32) | ⊢−−−■ −−−−4 | 0.050 |
| Lung (N=41) | 2.08 (1.08 - 4.01) | } ∎(| 0.028* |
| Melanoma (N=4) | 1.49 (0.34 – 6.62) | ⊢−−− + | 0.596 |
| MPN (N=7) | 1.10 (0.38 – 3.22) | F | 0.855 |
| NHL (N=37) | 1.45 (0.75 - 1.81) | F → ■ → → | 0.267 |
| Other (N=8) | 2.23 (0.73 - 6.83) | ⊢ | 0.161 |
| PCD (N=25) | 1.59 (0.75 - 3.37) | ⊢ | 0.226 |
| Sarcoma (N=11) | 0.49 (0.10 - 2.31) | ⊢−−−− | 0.368 |
| | | | $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$ |









0.05 0.1 0.2 0.5 2 1 5

20

10



А

Count

Figure 4

| Fable 1. Patient Demographics and | I Baseline Characteristics (r | า=304) |
|--|-------------------------------|--------|
|--|-------------------------------|--------|

| Characteristic | Number of Patients, n (%) | | |
|---|---------------------------|--|--|
| Age (years) | | | |
| < 18 years | 10 (3.29) | | |
| 18-29 | 3 (0.99) | | |
| 30-39 | 6 (1.97) | | |
| 40-49 | 34 (11.2) | | |
| 50-59 | 59 (19.4) | | |
| 60-69 | 90 (29.6) | | |
| 70-80 | 70 (23.03) | | |
| > 00 | 27 (8.88) | | |
| > 90 | 5 (1.04) | | |
| Male | 111 (17 1) | | |
| Female | 160 (52 6) | | |
| Race | 100 (02.0) | | |
| White | 182 (59.9) | | |
| Black | 55 (18.1) | | |
| Asian | 23 (7.57) | | |
| Other | 44 (14.5) | | |
| Underlying Cancer | | | |
| Breast cancer | 37 (12.2) | | |
| CNS cancers⁺ | 6 (1.97) | | |
| Germ cell tumors [¢] | 3 (1.0) | | |
| Lung cancer | 41 (13.5) | | |
| Gastrointestinal malignancies [∞] | 45 (14.8) | | |
| Genitourinary malignancies [∆] | 33 (10.9) | | |
| Gynecologic malignancies | 15 (4.93) | | |
| Head and neck cancers ⁹ | 7 (2.3) | | |
| Melanoma | 4 (1.32) | | |
| Sarcoma | 11 (2 1) | | |
| | 2 (6 2) | | |
| | 25 (8.6) | | |
| | 7 (2.2) | | |
| Myeloproliferative neoplasms | 20 (12 8) | | |
| | 59 (12.0) | | |
| Hodgkin lymphoma | 5 (1.64) | | |
| Other | 5 (1.64) | | |
| Neutropenia (ANC ≤ 1) | 55 (18.1) | | |
| All Inpatient G-CSF use | 25 (8.22) | | |
| Fligrastim Degulated filgrastim | 25 (8.22) | | |
| Neither | 275 (90 5) | | |
| Innatient G-CSE use prior to combined endoc | int only | | |
| Filorastim | 15 (4 93) | | |
| Pegylated filorastim | 1 (0.3) | | |
| Neither | 288 (94 7) | | |
| Supplemental 02** | 200 (94.7) | | |
| Room air | 105 (34.5) | | |
| Low O2 (≤ 4 L of O2) | 45 (14.8) | | |
| High O2 (> 4 L of O2)*** | 103 (35.3) | | |
| Mechanical Ventilation | 51 (16.8) | | |
| Death | 53 (17.4) | | |

** Highest oxygen requirement during hospitalization

*** Includes high flow nasal oxygen, non rebreather mask, bilevel positive airway pressure

CNS cancers¹ = Astrocytoma, glioblastoma, glioma, nerve sheath tumor, neuroblastoma

Germ cell tumors $^{\varphi}$ = Germ cell tumor and testicular cancer

 $\label{eq:Gastrointestinal malignancies} \ensuremath{^{\circ\circ}}\xspace = \ensuremath{\mathsf{Appendiceal}}\xspace, \ensuremath{\mathsf{cholangiocarcinoma}}\xspace, \ensuremath{\mathsf{gastrim}}\xspace, \ensurem$

Gentourinary malignancies^{Δ} = Bladder cancer, urothelial cancer, prostate cancer, renal cell carcinoma **Gynecologic malignancies**^{\forall} = cervical, endometrial, ovarian, uterine, vulvar

Head and neck cancers^{\Im} = squamous cell cancer (head and neck), adenoid cystic carcinoma, thyroid Acute and chronic leukemias[†] = acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, hairy cell leukemia, myelodysplastic syndrome

Plasma cell dyscrasias[‡] = amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance

Myeloproliferative neoplasms[▷] = aplastic anemia, immune thrombocytopenia purpura, Erdheim Chester, myelofibrosis.

Figure S1

| | | | HR (95% CI) | |
|-------------|--------------------|------------------------|---|---------|
| | | | : | P value |
| Age | 51-70 (N=147) | reference | ÷ | |
| | ≤25 (N=12) | 0.27 (0.06 – 1.29) | ⊢−−−− | 0.101 |
| | 26-50 (N=40) | 0.51 (0.28 - 0.93) | ⊢ | 0.027* |
| | 71-80 (N=70) | 1.19 (0.81 - 1.77) | ⊢ | 0.378 |
| | 81-90 (N=27) | 0.66 (0.34 - 1.27) | ⊢ | 0.208* |
| | >90 (N=5) | 7.03 (2.60 - 18.99) | ⊢ | |
| Neutropenia | (N=40) | 0.71 (0.34 - 1.50) | ⊢ | 0.367 |
| G-CSF | (N=16) | 3.01 (1.08 – 8.39) | · | 0.035* |
| Group | Breast (N=37) | reference | • | |
| | CNS (N=6) | 2.51 (0.66 – 9.50) | L | 0.175 |
| | GI (N=44) | 1.23 (0.63 - 2.41) | ⊢ | 0.546 |
| | GU (N=33) | 1.04 (0.48 – 2.26) | ⊢ | 0.924 |
| | Gyn (N=15) | 1.42 (0.57 – 3.51) | ┝━╪┲━━━┥ | 0.450 |
| | HL (N=5) | 0.37 (0.05 – 2.95) | L | 0.346 |
| | HNT (N=7) | 2.89 (1.03 – 8.07) | · | 0.044* |
| | Leukemia (N=21) | 2.05 (0.98 – 4.27) | ├──■ ──┥ | 0.055 |
| | (N=41) | 2.07 (1.07 – 3.98) | ⊢−− ■−−−4 | 0.030* |
| | Melanoma (N=4) | 1.47 (0.33 – 6.50) | ⊢−−−− | 0.612 |
| | MPN (N=7) | 1.28 (0.44 – 3.76) | | 0.650 |
| | NHL (N=37) | 1.45 (0.75 – 2.80) | ⊢⊢ ∎−−−4 | 0.274 |
| | Other (N=8) | 2.22 (0.73 – 6.81) | ⊢⊢ −−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− | 0.162 |
| | PCD (N=25) | 1.56 (0.74 – 3.31) | ⊢-¦ ∎4 | 0.247 |
| | Sarcoma (N=11) | 0.47 (0.10 – 2.23) | ⊢−−−−− | 0.345 |
| | | 0 | .05 0.1 0.2 0.5 1 2 5 1(| 0 20 |



Figure S3



Supplemental Table 1. Patient Demographics and Baseline Characteristics of Patients with Neutropenia (n=55) and G-CSF use (n=29)

| Characteristic | Neutropenia (N=55), n (%) | G-CSF use (N=29), n (%) |
|--|---------------------------|-------------------------|
| Age (years) | | |
| < 18 years | 7 (12.7) | 5 (17.2) |
| 18-29 | 1 (1.8) | 0 |
| 30-39 | 1 (1.8) | 1 (3.5) |
| 40-49 | 6 (10.9) | 4 (13.8) |
| 50-59 | 17 (30.9) | 8 (27.6) |
| 60-69 | 13 (23.6) | 6 (20.7) |
| >70 years | 10 (18.2) | 5(17.2) |
| Gender | | |
| Male | 36 (65.5) | 24 (82.8) |
| Female | 19 (35.5) | 5 (17.2) |
| Race | | |
| White | 31 (56.4) | 14 (48.3) |
| Black | 12 (21.8) | 8 (27.6) |
| Asian | 2 (3.6) | 1 (3.5) |
| Other/Inknown | 10 (18.2) | 6 (20.7) |
| Underlying Cancer* | | |
| Breast cancer | 10 (18.2) | 8 (27.6) |
| CNS ⁺ | 1 (1.8) | 1 (3.5) |
| Lung cancer | 6 (10.9) | 3 (10.3) |
| Gastrointestinal malignancies [∞] | 4 (7.3) | 2 (6.9) |
| Genitourinary malignancies [∆] | 2 (3.6) | 0 |
| Gynecologic malignancies $^{\vee}$ | 2 (3.6) | 1 (3.5) |
| Melanoma | 1 (1.8) | 1 (3.5) |
| Sarcoma | 2 (3.6) | 2 (6.9) |
| Acute and chronic leukemias [†] | 7 (12.7) | 3 (10.3) |
| Plasma cell dyscrasias [‡] | 6 (10.9) | 3 (10.35) |
| Myeloproliferative neoplasms [▷] | 1 (1.8) | 0 |
| Non-Hodgkin lymphoma | 12 (21.8) | 5 (17.2) |
| Other | 1 (1.8) | 0 |

CNS cancers¹ = Astrocytoma, glioblastoma, glioma, nerve sheath tumor, neuroblastoma

Germ cell tumors^{ϕ} = Germ cell tumor and testicular cancer

Gastrointestinal malignancies[∞] = Appendiceal, cholangiocarcinoma, gallbladder, gastrim, esophageal, hepatocellular, pancreatic, rectal/colon

Gentourinary malignancies^{Δ} = Bladder cancer, urothelial cancer, prostate cancer, renal cell carcinoma

Gynecologic malignancies $^{\sqrt{}}$ = cervical, endometrial, ovarian, uterine, vulvar

Acute and chronic leukemias[†] = acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphoid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, hairy cell leukemia,

myelodysplastic syndrome

Plasma cell dyscrasias[‡] = amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance

Supplemental Table 2. Outpatient Demographics and Baseline Characteristics (n=530)

| Characteristic | | Number of Patients, n (%) | |
|----------------|--------------------------------------|---------------------------|--|
| Age (year | rs) | | |
| | < 18 years | 12 (2.26) | |
| | 18-29 | 23 (4.34) | |
| | 30-39 | 39 (7.36) | |
| | 40-49 | 76 (14.3) | |
| | 50-59 | 133 (25.1) | |
| | 60-69 | 140 (26.4) | |
| | > 70 | 107 (20.2) | |
| Gender | | 000 (10 0) | |
| | Male | 263 (49.6) | |
| - | Female | 267 (50.4) | |
| Race | \ A //- ! 4 - | 005 (04.0) | |
| | VVNIte | 325 (61.3) | |
| | Agian | 69 (10.6) 51 (0.62) | |
| | Asidii Othor/Linknown | 64 (12.1) | |
| Underlyin | | 04 (12.1) | |
| Underlyn | Breast cancer | 105 (19 8) | |
| | Nervous system cancers | 10 (1 89) | |
| | Germ cell tumors | 8 (1.51) | |
| | Lung cancer | 33 (6.23) | |
| | Gastrointestinal malignancies | 90 (17.0) | |
| | Genitourinary malignancies | 71 (13.4) | |
| | Gynecologic malignancies | 24 (4.52) | |
| | Head and neck cancers | 23 (4.33) | |
| | Skin cancer | 15 (2.83) | |
| | Sarcoma | 35 (6.6) | |
| | Acute and chronic leukemias | 47 (8.86) | |
| | Plasma cell dyscrasias | 22 (4.15) | |
| | Myeloproliferative neoplasms | 4 (0.75) | |
| | Non-Hodgkin's and Hodgkin's lymphoma | 41 (7.73) | |
| | Other | 2 (0.4) | |
| Outpatier | nt G-CSF use | | |
| | Filgrastim | 11 (1.7) | |
| | Pegylated Filgrastim | 1 (0.2) | |
| | Neither | 518 (97.7) | |
| Death | | 21 (3.4%) | |

*Nervous system cancers include glioma, glioblastoma, astrocytoma, nerve sheath tumors, neuroblastoma; germ cell tumors include germ cell tumors and testicular cancer; gastrointestinal malignancies include orophyrangeal cancer, appendiceal cancer, cholangiocarcinoma, gallbladder cancer, gastrointestinal stromal tumors, pancreatic neuroendocrine tumors; genitourinary malignancies include bladder cancer, urothelial cancer, prostate cancer, renal cell carcinoma; gynecologic malignancies include cervical cancer, ovarian cancer, endometrial cancer, uterine cancer, vulvar cancer; head and neck cancers include head and neck squamous cell carcinoma, adenoid carcinoma, thyroid cancer, thymic tumors; skin cancers include melanoma and non-melanoma skin cancer; acute and chronic leukemias include acute and chronic myeloid leukemia, acute and chronic lymphocytic leukemia, hairy cell leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia; plasma cell dyscrasias include multiple myeloma, amyloidosis, smoldering myeloma, monoclonal gammopathy of undetermined significance; myeloproliferative neoplasms include myelofibrosis, immune thrombocytopenic purpura, aplastic anemia, Erdheim-Chester sydrome.

Supplemental Table 3

| | No G-CSF | G-CSF | G-CSF use prior to combined endpoint only |
|---------------|--------------|------------|--|
| Outpatient | | | |
| Death | 21/518 = 4% | 0/12 = 0% | N/A |
| | | | |
| Inpatient | | | |
| High O2 (>4L) | 94/275 = 34% | 9/29 = 31% | 7/16 = 44% |
| Vent | 47/275 = 17% | 4/29 = 14% | 1/16 = 6% |
| Death | 49/275 = 18% | 4/29 = 14% | 2/16 = 13% |

Supplemental Table 4

| Patient | Baseline Chest Xray: Normal (0) vs Abnormal (1) Pre- G-CSF | Follow up Chest Xray: Yes vs. No Post- G-CSF | Days between G-CSF and follow up Chest Xray | Evolution |
|---------|---|---|--|-----------|
| 1 | 1 | Yes | 2 | Increased |
| 2 | 0 | No | NA | NA |
| 3 | 1 | Yes | 13 | Decreased |
| 4 | 0 | Yes | 0 | Increased |
| 5 | 1 | Yes | 2 | Increased |
| 6 | NA | No | NA | NA |
| 7 | 1 | Yes | 2 | Decreased |
| 8 | 0 | Yes | 2 | Increased |
| 9 | 1 | Yes | 2 | Decreased |
| 10 | 0 | Yes | 0 | Unchanged |
| 11 | 1 | Yes | 5 | Increased |
| 12 | 0 | Yes | 1 | Increased |
| 13 | 1 | NA | NA | NA |
| 14 | 1 | NA | NA | NA |
| 15 | 1 | NA | NA | NA |
| 16 | NA | NA | NA | NA |